If you’ve already registered, please click here to log in to the webcast.

The spectrum of secondary immunodeficiency (SID) associated with B-cell lymphoproliferative diseases (B-CLPD) primarily encompasses defects in antibody production and hypogammaglobulinemia, alongside varying T cell and innate immunity defects.

As with primary immunodeficiency disorders (PID), a classification system is warranted to categorize SID defects and assess infection risk. Despite similarities in infection profiles between PID and SID to B-CLPD, it is of utmost importance to rule out PID at B-CLPD diagnosis, which has clinical and prognostic implications for the patients and their families.

This webcast will explore the genomic landscape of B-CLPD and its intersection with PID, underscoring potential shared pathways and therapeutic targets. A highlight will be an integrated approach incorporating immunological biomarkers alongside traditional prognostic indicators as essential for enhancing diagnostic accuracy and tailoring risk-adapted therapies in patients with B-CLPD and concurrent immune dysfunction.

• The clinical relevance of an adequate assessment and classification of B-CLPD immunodeficiency in predicting disease progression and informing treatment decisions
• Challenges in diagnosing primary versus secondary immunodeficiency and the importance of early recognition
• The relevance of interdisciplinary collaboration and integrated approaches to patient care